Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill
Executive Summary
Legislation in development also could create an option for tentative approval of interchangeable biosimilars.
You may also be interested in...
Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
US FDA Orphan Exclusivity Would Revert To Pre-Catalyst Status Under Senate Legislation
Federal court decision said the FDA cannot grant orphan exclusivity for subpopulations of a disease, which agency officials fear could damage pediatric rare disease drug development.